BTG Share Discussion Threads

[doctor 69] 23/4/2012 18:37

Anyone now expected sales to btg of varisolve in say 2016

[cumnor] 23/4/2012 18:06

Great stuff, totally novel technique and a massive market with so many unmet needs. Surgery itself is expensive and not without risk and of course anyone allowing someone inject 'unregulated' material into their legs now has the option hopefully of being treated with something safer, more effective and REGULATED. Frankly this news alone would justify the current share price and more, given the size of the market worldwide. Very decent trial as well. The big American pharmas will now be watching this, believe me. imo

[waterloo01] 23/4/2012 17:03

I like this bit. Could be on the market early 2013.

"BTG intends to submit a New Drug Application in the US, seeking approval of PEM as a comprehensive treatment for symptoms and appearance of varicose veins by the end of 2012".

Out of interest anyone know why I can't find these results on clinical gov site? Seems to show the trials but no recent Varisolve results. Am I looking in the wrong place?

[superbarnet] 23/4/2012 15:47

This was always going to subject to profit taking on a bad day for the market. We will know more next month once the french sort themselves out.

[cumnor] 23/4/2012 14:22

Agree, waterloo. This is a game changer. These phase111 results are highly significant and very very positive-far more convincing imo than most sucessful trial data presented to the FDA prior to most drug approvals. They are primarily interested in clinical data (overwhelming here) and safety data (as well).

[waterloo01] 23/4/2012 14:14

alan good point. Anyone who's been in this stock long knows how much has been invested in getting this to license. It seems that the trials and tribulations are finally going to pay off. Good day and long in coming.

The market size for a licensed treatment is significant/game changing for BTG.

[alanrussell] 23/4/2012 14:10

For my money this is the important bit.

"There were no cerebrovascular events or pulmonary emboli reported in any study"

V's efficacy has already been established, it was the safety question that caused the PIII suspension and share price crash last time.

[gregmorg] 23/4/2012 13:50

Alord53. As you requested I have copied a part of the statement.Note the last sentence. Whatever is said it seemed pretty clear to me in that the primary end point was not achieved. Prefer it to be different but there we are!

"A smaller study (VV017) evaluated patients treated first with heat ablation of the great saphenous vein (GSV) followed by treatment with PEM (0.5% and 1.0% dose concentrations) or placebo for the remaining visible varicosities. In this study, appearance was measured by co-primary endpoints, a blinded independent panel review of photographs and a patient-reported measure of appearance. Relative to baseline, all PEM treatment groups demonstrated a greater improvement in appearance than placebo by both measures. Statistical significance was achieved for the blinded independent panel review of photographs (p = 0.001) but not for the patient-reported measure of appearance, hence the primary objective of the study was not achieved."

[greenpastures2] 23/4/2012 13:28

Not sure if I have it right but in the VV017 trial it was where the patients were asked for their assessment where the end was not reached.

Could it be if you are witnessing a small improvement each day over the trial then you are less likely to think there is a big difference between beginning and endpoints?

[cumnor] 23/4/2012 13:24

Agree, re main Vanish1 trial. Highly significant and statistically important, mow confirming result of previous trial. We could not have asked for better result. Re smaller trail I would read that as a positive as well, re blinded assessment of results by independent examiners. Half the numbers and compunded by pre-treatment with a third vehicle. My reading in here is Varisolve across all the trails, incl the smaller statistically less significant one, surpasses all expectations and will become defacto Tx for VVs.

[a1ord53] 23/4/2012 13:15

GM I did read VV017 - nothing negative - could you please explain what negative you did find - thanks a lot

[doctor 69] 23/4/2012 13:12

Greg
That study met some if end points , but if size of study small , sometimes it is a size issue .
THE P VALUES IN OTHER STUDY SHOW MASSIVE EFFECT

[gregmorg] 23/4/2012 10:07

I note and am delighted with the sucess re Vanish 1. This second Phase 3 result confirms the results of the first Phase 3 result on Varisolve. However, no one seems to mention THE other study, VV017 referred to in this announcement,and which did not meet its primary endpoint! Admittedly it was a smaller study ie less then half the number of participants . However why is one study so very important and the negative study just ignored?

[cumnor] 23/4/2012 08:50

Poor market AMT. no worries.

[amt] 23/4/2012 08:42

market slow to wake up this morning. Managed to buy more at 383p This was always reckoned to be a potential blockbuster for BTG but seemed unlikely a few years ago to make it through all the testing. Now first class results could be transformational.

[cumnor] 23/4/2012 08:37

Really impressive trial as well. First regulated product in this expanding field set to supercede many far more expensive and traumatic surgical procedures. Also increasing patient awareness of importance of knowing the 'stuff' injected to them has been tested and trialled and now hopefully fully approved and that it is SAFE.

Recent call by ABPS (plastic surgeons) to ban lunchtime boob enlargement jobs using un-regulated 'fillers' (think concrete mix) because of scars or potentially worse only confirms there is a need for tighter regulation in these markets.

Varisolve will become the first hopefully in the VV field and medics will imo jump at it, mainly for safety reasons but now it is shown to work and because of medico-legal implications of using unregulated filler of very dubious pedigree. imo

[cumnor] 23/4/2012 08:20

Great news. AZN more likely to go fot BGC as clearly determined to rebuild portfolio by small bolt ons rather than a single big add (like SHP or FL) otherwise would be preserving it's cash pile. This news with Varisolve and GSK going for HGS just shows how valuable BTG really is. Need to move quick however as soon will be no minnow. imo

[doctor 69] 23/4/2012 08:18

yes but the buying continues the block of 40,000 at 385 just been bought, this is big buying , long may it continue

[toffeeman4] 23/4/2012 08:15

Astra buying company today, unfortunately not BTG but at 54% premium to market price.

[doctor 69] 23/4/2012 07:50

loss ,

i think the market is slowing factoring in , but not till £5

[toffeeman4] 23/4/2012 07:45

Good news, great way to start the week. Nice timing by company to release the news. Lets hope the markets perform.

[loss-leader] 23/4/2012 07:44

Bet the market knew about this last week. I expect a flat day. ll

[moretimeforlife] 23/4/2012 07:21

This could take it to £5+ sooner than expected by most people.

Dum spiro spero

NAI/DYOR etc

[doctor 69] 23/4/2012 07:14

is the submission ahead of expectations as surely this means varisolve will be on the market in the next financial year.

stunnning stuff, the market has not properly factored in the likely sales.

[broadwood] 23/4/2012 07:11

Superb news. Not many hurdles left now.